Primary aldosteronism
Primary aldosteronism is a condition in which the adrenal glands make too much of the hormone aldosterone. MeSH describes the overproduction as leading the body to hold on to sodium and lose potassium, with high blood pressure and low blood potassium as a result. A US government lab-test page says primary aldosteronism, also called Conn syndrome, is usually caused by a benign tumor on an adrenal gland. The test used to look for it measures aldosterone, commonly together with renin. An open-access review names it as the most common secondary cause of high blood pressure to look for when blood pressure stays high despite treatment.
Also called Conn syndrome
- Condition
- In this atlas
Overview
Technical summary
MeSH D006929 (Hyperaldosteronism) with a broad match, last updated 2010-06-25: the MeSH heading covers overproduction of aldosterone in general, and the page rests on its scope note plus a MedlinePlus aldosterone test page that names primary aldosteronism and Conn syndrome. The link to resistant hypertension rests on PMC8911440 (CC BY 4.0). The lab-test symptom list is for "too much ALD" and does not separate primary from other causes. No treatment guidance, frequency figure or trial result is recorded on this page.
Recognition
A US government lab-test page lists high blood pressure, low potassium and/or high sodium test results, muscle weakness, cramps and spasms, fatigue, headache, arrhythmia, and increased thirst and urination as symptoms of too much aldosterone, without separating primary aldosteronism from other causes.
Classification codes
-
D006929
Burden
No burden claims are published.
Claims and evidence
No claims are published for this condition yet.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact Evaluated for this: Spironolactone
Applies to Recipient not specified Patients with NYHA class III to IV heart failure (reduced ejection fraction), hypertension, edema or primary hyperaldosteronism, as described in the US label of Aldactone tablets
Population, setting and follow-up
- Patients described in the indications section of the label: people with NYHA class III to IV heart failure and reduced ejection fraction, people with hypertension, adults with edema from cirrhosis of the liver or the nephrotic syndrome, and people with primary hyperaldosteronism. The passages read do not state an age range for each use.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Not stated for each use in the label passages read
- Gestational age Not reported
- Postnatal age Not reported
The US label of Aldactone (spironolactone tablets, Pfizer Laboratories Div Pfizer Inc, application NDA012151; the version dated 2025-11-28 in openFDA) describes spironolactone as an aldosterone antagonist. It lists the treatment of NYHA class III to IV heart failure with reduced ejection fraction to increase survival, manage edema and reduce the need for hospitalization for heart failure; add-on treatment of hypertension; the management of edema in cirrhosis of the liver and in the nephrotic syndrome in the settings the label names; and treatment of primary hyperaldosteronism, as short-term preoperative treatment and as long-term maintenance therapy in the settings the label names.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label says the heart failure use is usually together with other heart failure therapies; that is not an atlas recommendation. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 8
Record details
- Record id
cardio:primary-aldosteronism- Content hash
e16c151dd0c81de5f8ec97c7765ecb0f647d4a99fac0e32c4f19e98b8602f0ab